A recent study in JAMA Pediatrics reveals that fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications, such as puberty blockers or hormones, between 2018 and 2022. Researchers analyzed insurance claims for over 5 million youths aged 8–17, finding only 926 received puberty blockers and 1,927 received hormones. No patients under age 12 were prescribed hormones, suggesting cautious medical practices.
Lead author Landon Hughes emphasized that the data contradicts exaggerated claims about widespread use. “It’s certainly not happening at the rate people often think,” Hughes stated.
The findings emerge as 26 states have enacted laws restricting or banning gender-affirming care for minors, many of which face legal challenges. A key Supreme Court decision in a Tennessee case is expected this year.
The study did not examine surgeries, which remain rare among transgender youth, nor Medicaid-covered patients.
Read More
Associated Press Rating
Discover more from News Facts Network
Subscribe to get the latest posts sent to your email.
